Two Sigma Investments’s Candel Therapeutics CADL Stock Holding History
Bought
Maintained
Sold
Other funds holding CADL
ACA
SVCM
Two Sigma Investments's CADL Position: Q3 2026 in Review
Two Sigma Investments reduced its Candel Therapeutics (CADL) stake by 22% in Q3 2026, selling an estimated $80.5K and leaving 25,470 shares worth $266K. The position accounts for ﹤0.01% of the portfolio, ranked #4414.
Two Sigma Investments first reported a position in CADL in Q1 2024 and has held it in 7 quarters since. The position peaked at $1.87M in Q2 2025. 141 funds tracked by Wall St. Rank hold CADL as of Q3 2026.
- Two Sigma Investments held 25,470 shares of Candel Therapeutics worth $266K as of Q3 2026.
- Two Sigma Investments sold 7,261 Candel Therapeutics shares in Q3 2026, an estimated $80.5K.
- Candel Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q3 2026, its #4414 holding.
- Two Sigma Investments first reported a position in Candel Therapeutics in Q1 2024 and has held it in 7 quarters since.
- Two Sigma Investments's Candel Therapeutics position peaked at $1.87M in Q2 2025.
- 141 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.
Based on Two Sigma Investments's 13F filing for Q3 2026, filed 16 Nov 2026.